Skip to main content

Table 5 Global response rates in all predefined patients subgroups among MITT patients

From: Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

Subgroup Anidulafungin
  Global success % [n /N] 95% CI
Neutropenic statusa   
  ANC ≤ 500/mm3 50.0 [1/2] 1.3–98.7
  ANC > 500/mm3 75.7 [28/37] 58.8–88.2
Baseline pathogensb   
  Candida albicans 71.4 [10/14] 41.9–91.6
  C. glabrata 66.7 [4/6] 22.3–95.7
  C. parapsilosis 100.0 [4/4] 39.8–100.0
  C. rugosa 100.0 [1/1] 2.5–100.0
  C. tropicalis 72.2 [13/18] 46.5–90.3
Previous surgeryc   
  Any surgery 84.6 [11/13] 54.6–98.1
  Abdominal surgery 87.5 [7/8] 47.3–99.7
Organ transplantation   
  Kidney, liver, or heart 0.0 [0/0] Not applicable
Elderly status   
  Age ≥ 65 years 58.8 [10/17] 32.9–81.6
Renal insufficiency   
  Creatinine clearance < 30 ml/min 54.5 [6/11] 23.4–83.3
Use of central venous catheterc   
  Yes 81.0 [17/21] 58.1–94.6
Receiving chemotherapyd   
  Yes 71.4 [5/7] 29.0–96.3
  1. a Patients with a missing ANC were not included.
  2. b A patient could have had more than one baseline pathogen.
  3. c Up to 1 month before the baseline visit.
  4. d Up to 3 months before the baseline visit.
  5. Abbreviations used: ANC, absolute neutrophil count; CI, confidence interval; MITT, modified intent-to-treat.